
Clinical TrialNov 17, 2026, 08:01 AM
Annovis Bio's Alzheimer's Trial Receives Second Positive DSMB Safety Recommendation
AI Summary
Annovis Bio, Inc. announced that an independent Data and Safety Monitoring Board (DSMB) has issued its second consecutive positive recommendation for their pivotal Phase 3 trial in early Alzheimer's disease, DUET-AD. This recommendation is based on the review of safety data accumulated through September 22, 2026, from 861 patients. The DSMB recommended the trial continue without modification. The company expects to report detailed safety outcomes and 6-month symptomatic results in March 2027.
Key Highlights
- Annovis Bio's Phase 3 DUET-AD trial for early Alzheimer's disease received a second consecutive positive recommendation from the DSMB.
- The recommendation was based on safety data from 861 patients reviewed through September 22, 2026.
- The DSMB recommended the DUET-AD trial continue without modification.
- The company will report detailed DUET-AD safety outcomes and 6-month symptomatic results in March 2027.
- Last patient, last visit for the 6-month treatment period is expected on December 31, 2026.
- Database lock for the trial is scheduled for February 8, 2027.
Price Impact
More from ANVS